Welcome to our dedicated page for CollPlant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on CollPlant Biotechnologies stock.
CollPlant Biotechnologies Ltd. develops regenerative and aesthetic medicine technologies based on plant-derived recombinant human collagen, or rhCollagen. News about CLGN centers on its BioInk and 3D bioprinting portfolio, including Collink.3D and BioFlex, as well as medical aesthetics programs such as photocurable dermal filler technology and tissue-regeneration applications.
Company updates also cover operating and financial results, distribution expansion for rhCollagen and BioInk products, Vergenix STR commercialization, intellectual-property activity, collaboration developments, capital actions and Nasdaq listing-compliance matters.
CollPlant (CLGN)/b) will host an investor webinar featuring its subsidiary LightSolver on September 17, 2026, at 8:30 a.m. Eastern Time.LightSolver management will introduce the company and its pure photonic computing technology, including its full-stack Laser Processing Unit (LPU) architecture, targeted computational challenges and applications, current validation and collaboration programs, and its roadmap toward commercial deployment. LightSolver became a subsidiary of CollPlant following completion of an acquisition announced on September 3, 2026, which expands CollPlant’s activities into advanced photonic computing alongside its existing regenerative medicine and 3D bioprinting businesses.
CollPlant Biotechnologies (CLGN) appointed Dr. Ruti Ben Shlomi, CEO and Co‑Founder of LightSolver, to its Board of Directors, effective immediately following the completion of CollPlant's acquisition of LightSolver announced on September 3, 2026.
LightSolver develops a proprietary Laser Processing Unit (LPU), an all‑optical, energy‑efficient photonic computing platform designed to accelerate computationally intensive workloads in scientific simulation, engineering, optimization and Physical AI. CollPlant states that Dr. Ben Shlomi's deep expertise in photonic computing and entrepreneurship will support the commercialization of this newly acquired technology.
With the LightSolver acquisition, CollPlant expands from regenerative medicine into advanced high‑performance computing, aiming to address demanding workloads in aerospace, defense and Physical AI while continuing its collagen-based 3D bioprinting, tissue repair and medical aesthetics activities.
CollPlant Biotechnologies (CLGN) completed its previously announced acquisition of Israeli deep-tech company LightSolver, formally entering the high-performance computing and photonics sectors.
LightSolver develops the Laser Processing Unit (LPU), a proprietary all‑optical, laser-based computing architecture designed to accelerate highly computational workloads such as scientific and engineering simulations, partial differential equations, large-scale linear systems and optimization. These capabilities target applications across aerospace, defense, energy, advanced engineering, financial services and Physical AI.
The transaction used an equity-centric structure. At closing, CollPlant issued upfront ordinary shares, pre-funded warrants and made a $5 million investment in LightSolver, with additional milestone-based warrants to become exercisable if specified technological and commercial objectives are achieved. CollPlant states that photonic computing activities will run alongside its existing regenerative medicine operations, which are based on its recombinant human collagen and 3D bioprinting platforms.
CollPlant (Nasdaq: CLGN) announced that its board has approved a one-for-ten reverse share split of its ordinary shares, following shareholder approval at the August 18, 2026 extraordinary general meeting. The split will take effect at the opening of trading on September 4, 2026, when CLGN will begin trading on a split-adjusted basis.
According to CollPlant, the reverse split is part of its strategic plan to regain compliance with Nasdaq’s minimum bid price requirement. Fractional shares will be rounded to the nearest whole share, and all outstanding options and warrants will be proportionately adjusted. The new CUSIP will be M2R51X124.
CollPlant (Nasdaq: CLGN) signed a definitive agreement to acquire Israeli deep-tech company LightSolver, which is developing a pure photonic computing architecture centered on its Laser Processing Unit™ (LPU™). The LPU is designed as an all-optical computing layer alongside CPUs and GPUs, targeting high-intensity workloads in simulation, optimization and Physical AI, with commercial availability targeted for 2028.
According to CollPlant, consideration includes 3,734,476 new ordinary shares (19.7% of pre-deal share capital), pre-funded warrants for 6,134,363 shares, and milestone-based warrants for 224,078,345 shares, plus rollover options for 2,261,966 shares, largely exercisable upon LightSolver achieving specified technological and commercial milestones and subject to shareholder approval above an equity blocker.
CollPlant Biotechnologies (Nasdaq: CLGN) entered a definitive agreement for a $2.6 million private placement, issuing 7,647,061 ordinary shares (or equivalents) plus series A and B warrants. Securities are priced at $0.34 per share and accompanying warrants, with closing expected on or about July 1, 2026.
Series A and B warrants, both with a $0.34 exercise price, cover up to 22,941,183 shares in total and become exercisable on the shareholder approval date. Net proceeds will fund working capital, R&D and evaluation of strategic transactions.
CollPlant Biotechnologies (NASDAQ: CLGN) reported Q1 2026 GAAP revenue of $73,000, down from $2.1 million in Q1 2025, mainly due to a non-recurring $2.0 million milestone last year. GAAP net loss widened to $3.1 million ($0.23/share). Cash and equivalents were $4.3 million after a $1.7 million February 2026 offering.
The company advanced its rhCollagen-based medical aesthetics pipeline, including a photocurable dermal filler in final preclinical stage, gained a Korean patent on this technology, launched the BioFlex DLP bioprinting kit, cut operating expenses via a ~50% headcount reduction, and began reviewing strategic alternatives.
CollPlant (NASDAQ: CLGN) announced termination of its development agreement with AbbVie and a companywide cost-reduction plan including ~50% workforce reduction. The company said the actions extend its cash runway into Q4 2026 and it is actively pursuing new strategic partners across aesthetics while advancing three core programs: regenerative fillers, breast implants, and rhCollagen bioinks.
CollPlant also launched the BioFlex DLP bioink kit and expanded North American distribution via a cGMP logistics hub to support clinical supplies and commercial growth.
CollPlant (Nasdaq: CLGN) reported 2025 results: GAAP revenue $2.37M vs $0.52M in 2024, driven by a $2.0M AbbVie milestone. GAAP net loss narrowed to $11.5M ($0.94/sh) from $16.6M. Cash was $5.6M at year-end amid a 25% workforce reduction and cost‑cutting.
Operational highlights include new patents in the U.S., South Korea and Japan, BioFlex launch for DLP bioprinting, expanded North American distribution, and encouraging preclinical data for regenerative breast implants.
CollPlant (Nasdaq: CLGN) received a Nasdaq notice on March 23, 2026, for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2). The company has a 180-calendar day cure period until September 21, 2026 to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days.
The company may seek a second 180-day period if it meets market value and other initial listing standards and notifies Nasdaq of intent to cure, potentially via a reverse share split. Ordinary shares remain listed and tradable.